1,3,4-Oxadiazole-containing histone deacetylase inhibitors: Anticancer activities in cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 6259-6265

  Valente, Sergio ^a   Trisciuoglio, Daniela ^b   De Luca, Teresa ^b   Nebbioso, Angela ^c   Labella, Donatella ^a   Lenoci, Alessia ^a   Bigogno, Chiara ^d   Dondio, Giulio ^d   Miceli, Marco ^c   Brosch, Gerald ^e   Del Bufalo, Donatella ^b   Altucci, Lucia ^c,f   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Aphad Srl   (Italy)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; ALPHA TUBULIN; ANILIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HYDROXAMIC ACID; N (2 AMINOPHENYL) 3 (4 (5 ARYL ARYLALKYL 1,3,4 OXADIAZOL 2 YL)PHENYL)ACRYLAMIDE; N (2 AMINOPHENYL) 4 ((5 (NAPHTHALEN 1 YLMETHYL) 1,3,4 OXADIAZOL 2 YL)METHYL)BENZAMIDE; N HYDROXY 3 (4 (5ARYL ARYLALKYL 1,3,4 OXADIAZOL 2 YL)PHENYL)ACRYLAMIDE; N HYDROXY 4 ((5 (NAPHTHALEN 1 YLMETHYL) 1,3,4 OXADIAZOL 2 YL)MEHTYL)BENZAMIDE; PROTEIN P21; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GRANULOCYTE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MYELOID LEUKEMIA CELL LINE; U937 CELL LINE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; MOLECULAR STRUCTURE; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84904962606     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500303u     Document Type: Article

References (17)

1. Clayton, A. L.; Hazzalin, C. A.; Mahadevan, L. C. Enhanced histone acetylation and transcription: a dynamic perspective Mol. Cell 2006, 23, 289-296
2. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins Gene 2005, 363, 15-23
3. Mai, A. Small-molecule chromatin-modifying agents: therapeutic applications Epigenomics 2010, 2, 307-324
4. Benedetti, R.; Conte, M.; Altucci, L. Targeting HDACs in diseases: where are we? Antioxid. Redox Signaling 2014, Mar 6, PMID 24382114, DOI 10.1089/ars.2013.5776.
5. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nature Biotechnol. 2007, 25, 84-90
6. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma Drugs Today 2009, 45, 787-795
7. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy Med. Res. Rev. 2005, 25, 261-309
8. Li, J.; Li, G.; Xu, W. Histone deacetylase inhibitors: an attractive strategy for cancer therapy Curr. Med. Chem. 2013, 20, 1858-1886
9. Valente, S.; Conte, M.; Tardugno, M.; Massa, S.; Nebbioso, A.; Altucci, L.; Mai, A. Pyrrole-based hydroxamates and 2-aminoanilides: histone deacetylase inhibition and cellular activities ChemMedChem 2009, 4, 1411-1415 and references cited therein.
10. Valente, S.; Tardugno, M.; Conte, M.; Cirilli, R.; Perrone, A.; Ragno, R.; Simeoni, S.; Tramontano, A.; Massa, S.; Nebbioso, A.; Miceli, M.; Franci, G.; Brosch, G.; Altucci, L.; Mai, A. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity ChemMedChem 2011, 6, 698-712 and references cited therein.
11. Mai, A.; Perrone, A.; Nebbioso, A.; Rotili, D.; Valente, S.; Tardugno, M.; Massa, S.; De Bellis, F.; Altucci, L. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities Bioorg. Med. Chem. Lett. 2008, 18, 2530-2535 and references cited therein.
12. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M. C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M. J.; Lo Surdo, P.; Carfi, A.; Koch, U.; De Francesco, R.; Steinkühler, C.; Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 17335-17340
13. Trisciuoglio, D.; Ragazzoni, Y.; Pelosi, A.; Desideri, M.; Carradori, S.; Gabellini, C.; Maresca, G.; Nescatelli, R.; Secci, D.; Bolasco, A.; Bizzarri, B.; Cavaliere, C.; D'Agnano, I.; Filetici, P.; Ricci-Vitiani, L.; Rizzo, M. G.; Del Bufalo, D. CPTH6, a thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells Clin. Cancer Res. 2012, 18, 475-486
14. Nebbioso, A.; Manzo, F.; Miceli, M.; Conte, M.; Manente, L.; Baldi, A.; De Luca, A.; Rotili, D.; Valente, S.; Mai, A.; Usiello, A.; Gronemeyer, H.; Altucci, L. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes EMBO Rep. 2009, 10, 776-782
15. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E. M.; Ferrara, F.; Bresciani, F.; Weisz, A.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nature Med. 2005, 11, 77-84
16. Altucci, L.; Rossin, A.; Raffelsberger, W.; Reitmair, A.; Chomienne, C.; Gronemeyer, H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL Nature Med. 2001, 7, 680-686
17. Valente, S.; Trisciuoglio, D.; Tardugno, M.; Benedetti, R.; Labella, D.; Secci, D.; Mercurio, C.; Boggio, R.; Tomassi, S.; Di Maro, S.; Novellino, E.; Altucci, L.; Del Bufalo, D.; Mai, A.; Cosconati, S. tert -Butylcarbamate- containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells ChemMedChem 2013, 8, 800-811